text_1: UK cost agency rejects leukaemia drug from J&J and AbbVie.
text_2: A new leukaemia drug viewed by industry experts as a future blockbuster has been rejected by Britain’s healthcare cost-effectiveness agency NICE, which said it could not be confident the medicine represented an effective use of resources.